Teva Receives Favorable Ruling on Treanda Patent-Infringement SuitBy
Teva Pharmaceutical Industries Ltd. reports that the United States District Court for the District of Delaware has ruled in favor of Teva in the company’s patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva’s Treanda (bendamustine hydrochloride) for injection, a drug to treat chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
At trial, the defendants alleged that certain claims of US Patents 8,436,190; 8,609,863; 8,791,270; and 8,895,756, listed in the Orange Book for Treanda were invalid. The defendants had previously stipulated to infringement of certain claims of these patents. Teva reported that the court issued a ruling affirming the validity of the relevant claims of all four patents. As a result, the company expects that the court will enter an order enjoining the defendants from launching their respective generic versions of Treanda until patent expiry in 2026.
Source: Teva Pharmaceutical Industries